Non-alcoholic fatty liver disease: its risk factors and it is as a risk factor

DOI: https://doi.org/10.29296/25877305-2019-12-22
Download full text PDF
Issue: 
12
Year: 
2019

Yu. Evsyutina, Candidate of Medical Sciences; National Medical Research Center for Preventive Medicine, Ministry of Health of Russia, Moscow

The prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide is 25%; this rate is much higher in the Russian Federation. NAFLD is closely associated with obesity, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular diseases. Patients with NAFLD have a significantly increased risk for cirrhosis, terminal liver failure requiring liver transplantation, as well as hepatocellular carcinoma and mortality (overall, cardiovascular and liver-related). The prevention and treatment of NAFLD are aimed at correcting modifiable risk factors, primarily at losing weight (by 7–10% of the baseline value) through moderate physical activity per day and a low-calorie diet.
Keywords: 
gastroenterology
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
hepatocellular carcinoma
diet
physical activity

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Younossi Z., Koenig A., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. – 2016; 64: 73–84. DOI: 10.1002/hep.28431.
  2. Chalasani N., Younossi Z., Lavine J. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases // Hepatology. – 2018; 67: 328–57. DOI: 10.1002/hep.29367.
  3. Sung K., Kim B., Cho Y. et al. Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline // BMC Gastroenterology. – 2012; 12: 84. DOI: 10.1186/1471-230X-12-84.
  4. Xu C., Yu C., Ma H. et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study // Am. J. Gastroenterol. – 2013; 108 (8): 1299–304. DOI: 10.1038/ajg.2013.104.
  5. Lee K. Metabolic syndrome predicts the incidence of hepatic steatosis in Koreans // Obes. Res. Clin. Pract. – 2010; 4 (3): e217–e224. DOI: 10.1016/j.orcp.2010.02.004.
  6. Hamabe A., Uto H., Imamura Y. et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period // J. Gastroenterol. – 2011; 46 (6): 769–78. Doi: 10.1007/s00535-011-0376-z.
  7. Kim N., Kim J., Kim Y. et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects // Liver Int. – 2014; 34 (4): 604–11. DOI: 10.1111/liv.12454.
  8. Koehler E., Schouten J., Hansen B. et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study // J. Hepatol. – 2012; 57: 1305–11. DOI: 10.1016/j.jhep.2012.07.028.
  9. Frith J., Day C., Henderson E. et al. Non-alcoholic fatty liver disease in older people // Gerontology. – 2009; 55: 607–13. DOI: 10.1159/000235677.
  10. Masuoka H., Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals // Ann. NY Acad. Sci. – 2013; 1281: 106–22. DOI: 10.1111/nyas.12016.
  11. Dongiovanni P., Anstee Q., Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment // Curr. Pharm. Des. – 2013; 19: 5219–38. DOI: 10.2174/13816128113199990381.
  12. Sasaki A., Nitta H., Otsuka K. et al. Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments // Front Endocrinol. – 2014; 5: 164. DOI: 10.3389/fendo.2014.00164.
  13. Subichin M., Clanton J., Makuszewski M. et al. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery // Surg. Obes. Relat. Dis. – 2015; 11: 137–41. DOI: 10.1016/j.soard.2014.06.015.
  14. Byrne C., Targher G. NAFLD: a multisystem disease // J. Hepatol. – 2015; 62: S47–64. DOI: 10.1016/j.jhep.2014.12.012.
  15. Prashanth M., Ganesh H., Vima M. et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus // J. Assoc. Physicians India. – 2009; 57: 205–10. DOI: 10.1155/2016/3805372.
  16. Fan N., Zhang L., Xia Z. et al.Sex-specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients // J. Diabetes Res. – 2016; 2016: 3805372. DOI: 10.1155/2016/3805372.
  17. Younossi Z., Anstee Q., Marietti M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention // Nat. Rev. Gastroenterol. Hepatol. – 2018; 15 (1): 11–20. DOI: 10.1038/nrgastro.2017.109.
  18. George E., Forsyth A., Itsiopoulos C. et al. Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults // Adv. Nutr. – 2018; 9 (1): 30–40. DOI: 10.1093/advances/nmx007.
  19. Ma J., Hennein R., Liu C. et al. Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease // Gastroenterology. – 2018; 155: 107–17. DOI:10.1053/j.gastro.2018.03.038.
  20. St George A., Bauman A., Johnston A. et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease // Hepatology. – 2009; 50: 68–76. DOI: 10.1002/hep.22940.
  21. Sung K.-C., Ryu S. Lee J.-Y. et al. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver // J. Hepatol. – 2016; 65: 791–7. DOI: 10.1016/j.jhep.2016.05.026.
  22. Orci L., Gariani K., Oldani G. et al. Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression // Clin. Gastroenterol. Hepatol. – 2016; 14 (10): 1398–411. DOI: 10.1016/j.cgh.2016.04.036.
  23. Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: management of nonalcoholic fatty liver disease // Clin. Mol. Hepatol. – 2013; 19: 325–48. DOI: 10.3350/cmh.2013.19.4.325.
  24. Abdelmalek M., Suzuki A., Guy C. et al. Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease // Hepatology. – 2010; 51 (6): 1961–71. DOI: 10.1002/hep.23535.
  25. Lieber C., Weiss D., Groszmann R. et al. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease // Alcohol Clin. Exp. Res. – 2003; 27 (11): 1765–72. DOI: 10.1097/01.ALC.0000093743.03049.80.
  26. Younossi Z., Otgonsuren M., Henry L. et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 // Hepatology. – 2015; 62: 1723–30. DOI: 10.1002/hep.28123.
  27. Kanwal F., Kramer J., Mapakshi S. et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease // Gastroenterology. – 2018; 155 (6): 1828–37.e2. DOI: 10.1053/j.gastro.2018.08.024.
  28. Younossi Z. Non-alcoholic fatty liver disease – A global public health perspective // J. Hepatol. – 2019; 70 (3): 531–44. DOI: 10.1016/j.jhep.2018.10.033.
  29. Wong R., Aguilar M., Cheung R. et al. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States // Gastroenterology. – 2015; 148 (3): 547–55. DOI: 10.1053/j.gastro.2014.11.039.
  30. Angulo P., Kleiner D., Dam-Larsen S. et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease // Gastroenterology. – 2015; 149: 389––97.e10. DOI: 10.1053/j.gastro.2015.04.043.